Literature DB >> 18508571

The genetics of malignant melanoma.

Jesus Lomas1, Pilar Martin-Duque, Mar Pons, Miguel Quintanilla.   

Abstract

Melanoma probably is the most aggressive cancer in humans and remains one of the leading causes of cancer death in developed countries. This review summarizes the most important alterations in protooncogenes and tumor suppressor genes that contribute to the pathogenesis of malignant melanoma, with a special emphasis on the involved signaling pathways. Our knowledge of the molecular biology of melanoma has been benefited from recent advances on high-throughput technologies analyzing wide genomic and gene expression profiles that have uncovered unknown candidate genes. To test the interactions between distinct pathways and of those with the environment a wealth of genetically modified animal models has been generated over the past years. Other studies have focused on the isolation of melanoma stem cells and on the characterization of signaling pathways that contribute to their survival and maintenance. A consequence of all these studies is the emergence of potential new strategies that could improve the still inadequate arsenal of therapeutic tools to fight against this fatal disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508571     DOI: 10.2741/3065

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  8 in total

1.  Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.

Authors:  Nicolas Dumaz
Journal:  Small GTPases       Date:  2011-09-01

Review 2.  Circulating serologic and molecular biomarkers in malignant melanoma.

Authors:  Shanique R Palmer; Lori A Erickson; Ilia Ichetovkin; Daniel J Knauer; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

3.  TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.

Authors:  F Journe; H Id Boufker; L Van Kempen; M-D Galibert; M Wiedig; F Salès; A Theunis; D Nonclercq; A Frau; G Laurent; A Awada; G Ghanem
Journal:  Br J Cancer       Date:  2011-11-01       Impact factor: 7.640

4.  New Perspectives of "omics" Applications in Melanoma Research.

Authors:  Carmen Rodríguez-Cerdeira; Alberto Molares-Vila
Journal:  Open Biochem J       Date:  2011-12-30

5.  Stage-specific prognostic biomarkers in melanoma.

Authors:  Yabin Cheng; Jing Lu; Guangdi Chen; Gholamreza Safaee Ardekani; Anand Rotte; Magdalena Martinka; Xuezhu Xu; Kevin J McElwee; Guohong Zhang; Youwen Zhou
Journal:  Oncotarget       Date:  2015-02-28

6.  Insulin-like-growth-factor-binding-protein-3 (IGFBP-3) contrasts melanoma progression in vitro and in vivo.

Authors:  Antimo Naspi; Vincenzo Panasiti; Franco Abbate; Vincenzo Roberti; Valeria Devirgiliis; Michela Curzio; Martina Borghi; Francesco Lozupone; Simone Carotti; Sergio Morini; Eugenio Gaudio; Stefano Calvieri; Paola Londei
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

7.  Tetrahydroanthraquinone Derivative (±)-4-Deoxyaustrocortilutein Induces Cell Cycle Arrest and Apoptosis in Melanoma Cells via Upregulation of p21 and p53 and Downregulation of NF-kappaB.

Authors:  Miroslav Genov; Birgit Kreiseder; Michael Nagl; Elisabeth Drucker; Martina Wiederstein; Barbara Muellauer; Julia Krebs; Teresa Grohmann; Dagmar Pretsch; Karl Baumann; Markus Bacher; Alexander Pretsch; Christoph Wiesner
Journal:  J Cancer       Date:  2016-03-12       Impact factor: 4.207

Review 8.  Biomarkers in melanoma.

Authors:  H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.